Riddle, Matthew C.

One‐year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal‐time insulin: the EDITION 1 12‐month randomized trial, including 6‐month extension

Riddle, M. C., Yki‐Järvinen, H., Bolli, G. B., Ziemen, M., Muehlen‐Bartmer, I., Cissokho, S., & Home, P. D. (2015) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 110

Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes

Riddle, M. C., Cefalu, W. T., Evans, P. H., Gerstein, H. C., Nauck, M. A., Oh, W. K., Rothberg, A. E., le Roux, C. W., Rubino, F., Schauer, P., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 92

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND

Konig, M., Riddle, M. C., Colhoun, H. M., Branch, K. R., Atisso, C. M., Lakshmanan, M. C., Mody, R., Raha, S., & Gerstein, H. C. (2021) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 73

Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes

Riddle, M., Pencek, R., Charenkavanich, S., Lutz, K., Wilhelm, K., & Porter, L. (2009) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 66

Twenty‐four‐hour profiles of plasma glucose, insulin, C‐peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short‐term, medium‐dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion and action

Yuen, K. C. J., McDaniel, P. A., & Riddle, M. C. (2012) · Clinical Endocrinology

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 58

A1C targets should be personalized to maximize benefits while limiting risks

Riddle, M. C., Gerstein, H. C., Holman, R. R., Inzucchi, S. E., Zinman, B., Zoungas, S., & Cefalu, W. T. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 54

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

Dagenais, G. R., Rydén, L., Leiter, L. A., Lakshmanan, M., Dyal, L., Probstfield, J. L., Atisso, C. M., Shaw, J. E., Conget, I., Cushman, W. C., et al. (2020) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 35